Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Radiologic assessment confirming an acute middle cerebral artery ischemic stroke~* Index stroke occurred within the past 3-4 days~* Inpatient males and females~* Severe hemiparesis or hemiplegia defined by FMMS score less than or equal to (\</=) 35~* Sufficient speech, vision and hearing to participate in study evaluations~Exclusion Criteria:~* NIHSS greater than (\>) 20~* Severe aphasia that prevents a participant from following directions in rehabilitation~* Significant deficit from prior strokes or pre-existing motor deficit~* History of epilepsy, neurosurgery, severe head trauma or central nervous system infections that have residual symptomatology or have required treatment in the last 12 months~* Known or suspected clinical seizure post-index stroke~* History of pre-existing dementia or use of medications for dementia~* History of clinically significant pre-existing psychiatric conditions within 12 months prior to stroke~* Due to undergo carotid surgery within the next 4 months~* Enrollment/participation in any interventional study (clinical trial) involving an investigational drug (unapproved) or non-drug treatment within the prior 3 months or 6 times the half-life (whichever is longer)~* Clinically relevant medical conditions that would likely interfere with the study conduct and scheduled assessments~* Contraindication to magnetic resonance imaging (MRI) or conditions which render interpretation of MRI difficult

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Basmisanil (Type: EXPERIMENTAL): Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to basmisanil orally twice daily for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).